Vaccination immunity is vital to prevent widespread viral infection and
reduce morbidity and mortality. Patients with COVID-19 infection develop a
polyclonal active immune response to viral antigens. Antibodies that develop as a result
of this polyclonal immunity can neutralize the virus and prevent further infection in the
recovered host. The magnitude and duration of protection of a vaccine administered to
humans in society cannot be the same for every individual. The acquisition of
immunity depends on the functioning of the person's own immune system. Therefore, a
vaccine in the population is never 100 % protective. There are expectations that the
COVID-19 vaccine should have at least a 50% protection rate. Vaccine development
stages also require a process that can take years; therefore, the public will probably
hardly reach a vaccine that is safe and economical for public use in the near future. The
global medical community should search for effective ways to provide vaccination be
easily reached by vulnerable groups all over the world in order to secure healthy new
generations.
Keywords: COVID-19, Management, Vaccination, Vaccination immunity.
